Physicochemical and biopharmaceutical characterization of amorphous solid dispersion of nobiletin, a citrus polymethoxylated flavone, with improved hepatoprotective effects

European Journal of Pharmaceutical Sciences

Volumn 49, Issue 4, 2013, Pages 453-460

  Onoue, Satomi ^a   Nakamura, Tatsuya ^a   Uchida, Atsushi ^a   Ogawa, Kazunori ^b   Yuminoki, Kayo ^c   Hashimoto, Naofumi ^c   Hiza, Aiki ^a   Tsukaguchi, Yuta ^a   Asakawa, Tomohiro ^a   Kan, Toshiyuki ^a   Yamada, Shizuo ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b FOOD RESEARCH INSTITUTE   (Japan)

^c SETSUNAN UNIVERSITY   (Japan)

Author keywords

Dissolution; Hepatoprotection; Nobiletin; Oral absorption; Solid dispersion

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; NOBILETIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DISPERSION; DRUG BIOAVAILABILITY; DRUG SOLUBILITY; LIVER INJURY; LIVER PROTECTION; MALE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT; SCANNING ELECTRON MICROSCOPY;

EID: 84879245095     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2013.05.014     Document Type: Article

References (30)

1. Akachi, T., Shiina, Y., Ohishi, Y., Kawaguchi, T., Kawagishi, H., Morita, T., Mori, M., Sugiyama, K., 2010. Hepatoprotective effects of flavonoids from shekwasha (Citrus depressa) against D-galactosamine-induced liver injury in rats. J. Nutr. Sci. Vitaminol. 56, 60-67.
2. Asakawa, T., Hiza, A., Nakayama, M., Inai, M., Oyama, D., Koide, H., Shimizu, K., Wakimoto, T., Harada, N., Tsukada, H., Oku, N., Kan, T., 2011. PET imaging of nobiletin based on a practical total synthesis. Chem. Commun. 47, 2868-2870.
3. Bataller, R., Brenner, D.A., 2005. Liver fibrosis. J. Clin. Invest. 115, 209-218. (Pubitemid 40385459)
4. Bergmeyer, H.U., Scheibe, P., Wahlefeld, A.W., 1978. Optimization of methods for aspartate aminotransferase and alanine aminotransferase. Clin. Chem. 24, 58-73. (Pubitemid 8262862)
5. Chiou, W.L., Riegelman, S., 1971. Pharmaceutical applications of solid dispersion systems. J. Pharm. Sci. 60, 1281-1302.
6. Choi, J.H., Kim, D.W., Yun, N., Choi, J.S., Islam, M.N., Kim, Y.S., Lee, S.M., 2011. Protective effects of hyperoside against carbon tetrachloride- induced liver damage in mice. J. Nat. Prod. 74, 1055-1060.
7. de Meijer, V.E., Sverdlov, D.Y., Popov, Y., Le, H.D., Meisel, J.A., Nose, V., Schuppan, D., Puder, M., 2010. Broad-spectrum matrix metalloproteinase inhibition curbs inflammation and liver injury but aggravates experimental liver fibrosis in mice. PLoS ONE 5, e11256.
8. Fu, Y., Zheng, S., Lin, J., Ryerse, J., Chen, A., 2008. Curcumin protects the rat liver from CCl4-caused injury and fibrogenesis by attenuating oxidative stress and suppressing inflammation. Mol. Pharmacol. 73, 399-409. (Pubitemid 351159210)
9. Gewiese-Rabsch, J., Drucker, C., Malchow, S., Scheller, J., Rose-John, S., 2010. Role of IL-6 trans-signaling in CCl(4)induced liver damage. Biochim. Biophys. Acta 1802, 1054-1061.
10. Gines, P., Cardenas, A., Arroyo, V., Rodes, J., 2004. Management of cirrhosis and ascites. New Engl. J. Med. 350, 1646-1654.
11. Hancock, B.C., Shamblin, S.L., Zografi, G., 1995. Molecular mobility of amorphous pharmaceutical solids below their glass transition temperatures. Pharm. Res. 12, 799-806.
12. Hayashi, S., Itoh, A., Isoda, K., Kondoh, M., Kawase, M., Yagi, K., 2008. Fucoidan partly prevents CCl4-induced liver fibrosis. Eur. J. Pharmacol. 580, 380-384.
13. Ishiwa, J., Sato, T., Mimaki, Y., Sashida, Y., Yano, M., Ito, A., 2000. A citrus flavonoid, nobiletin, suppresses production and gene expression of matrix metalloproteinase 9/gelatinase B in rabbit synovial fibroblasts. J. Rheumatol. 27, 20-25. (Pubitemid 30058624)
14. Kawabata, Y., Wada, K., Nakatani, M., Yamada, S., Onoue, S., 2011. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications. Int. J. Pharm. 420, 1-10.
15. Lechuga-Ballesteros, D., Abdul-Fattah, A., Stevenson, C.L., Bennett, D.B., 2003. Properties and stability of a liquid crystal form of cyclosporine-the first reported naturally occurring peptide that exists as a thermotropic liquid crystal. J. Pharm. Sci. 92, 1821-1831. (Pubitemid 37071815)
16. Leuner, C., Dressman, J., 2000. Improving drug solubility for oral delivery using solid dispersions. Eur. J. Pharm. Biopharm. 50, 47-60. (Pubitemid 30326688)
17. Li, R.W., Theriault, A.G., Au, K., Douglas, T.D., Casaschi, A., Kurowska, E.M., Mukherjee, R., 2006. Citrus polymethoxylated flavones improve lipid and glucose homeostasis and modulate adipocytokines in fructose-induced insulin resistant hamsters. Life Sci. 79, 365-373. (Pubitemid 44172805)
18. Linton, S.D., 2005. Caspase inhibitors: a pharmaceutical industry perspective. Curr. Top. Med. Chem. 5, 1697-1717.
19. Manthey, J.A., Cesar, T.B., Jackson, E., Mertens-Talcott, S., 2011. Pharmacokinetic study of nobiletin and tangeretin in rat serum by high-performance liquid chromatography-electrospray ionization-mass spectrometry. J. Agric. Food Chem. 59, 145-151.
20. Nagase, H., Yamakuni, T., Matsuzaki, K., Maruyama, Y., Kasahara, J., Hinohara, Y., Kondo, S., Mimaki, Y., Sashida, Y., Tank, A.W., Fukunaga, K., Ohizumi, Y., 2005. Mechanism of neurotrophic action of nobiletin in PC12D cells. Biochemistry 44, 13683-13691. (Pubitemid 41507449)
21. Onoue, S., Uchida, A., Takahashi, H., Seto, Y., Kawabata, Y., Ogawa, K., Yuminoki, K., Hashimoto, N., Yamada, S., 2011. Development of high-energy amorphous solid dispersion of nanosized nobiletin, a citrus polymethoxylated flavone, with improved oral bioavailability. J. Pharm. Sci. 100, 3793-3801.
22. Onoue, S., Kojo, Y., Aoki, Y., Kawabata, Y., Yamauchi, Y., Yamada, S., 2012. Physicochemical and pharmacokinetic characterization of amorphous solid dispersion of tranilast with enhanced solubility in gastric fluid and improved oral bioavailability. Drug Metab. Pharmacokinet. 27, 379-387.
23. Sato, H., Kawabata, Y., Yuminoki, K., Hashimoto, N., Yamauchi, Y., Ogawa, K., Mizumoto, T., Yamada, S., Onoue, S., 2012. Comparative studies on physicochemical stability of cyclosporine A-loaded amorphous solid dispersions. Int. J. Pharm. 426, 302-306.
24. Sepodes, B., Maio, R., Pinto, R., Marques, C., Mendes-do-Vale, J., McDonald, M.C., Thiemermann, C., Mota-Filipe, H., 2004. Tempol, an intracellular free radical scavenger, reduces liver injury in hepatic ischemia-reperfusion in the rat. Transplant. Proc. 36, 849-853. (Pubitemid 38766197)
25. Walle, T., 2007. Methoxylated flavones, a superior cancer chemopreventive flavonoid subclass? Semin. Cancer Biol. 17, 354-362. (Pubitemid 47369171)
26. Wang, F., Wen, T., Chen, X.Y., Wu, H., 2008. Protective effects of pirfenidone on Dgalactosamine and lipopolysaccharide-induced acute hepatotoxicity in rats. Inflamm. Res. 57, 183-188.
27. Weber, L.W., Boll, M., Stampfl, A., 2003. Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. Crit. Rev. Toxicol. 33, 105-136. (Pubitemid 36432872)
28. Yasuda, T., Yoshimura, Y., Yabuki, H., Nakazawa, T., Ohsawa, K., Mimaki, Y., Sashida, Y., 2003. Urinary metabolites of nobiletin orally administered to rats. Chem. Pharm. Bull. 51, 1426-1428. (Pubitemid 41694763)
29. Yoshikawa, T., Furukawa, Y., Wakamatsu, Y., Nishida, K., Takemura, S., Tanaka, H., Kondo, M., 1981. The protection of coenzyme Q10 against carbon tetrachloride hepatotoxicity. Gastroenterol. Jpn. 16, 281-285. (Pubitemid 11018764)
30. Yoshikawa, T., Furukawa, Y., Wakamatsu, Y., Kondo, M., 1982. Protection by BCG, levamisole, PS-K, OK-432, and vitamin E against carbon tetrachloride hepatotoxicity. Hepatogastroenterology 29, 240-242. (Pubitemid 13065518)